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Abstract
Background:  The hypothalamo-pituitary-adrenal (HPA) axis modulates the inflammatory
response during sepsis. Macrophage migration inhibitory factor (MIF), which counteracts the anti-
inflammatory activity of glucocorticoid (GC), is one of the mediators of the development of
inflammation. An inflammatory imbalance involving GC and MIF might be the cause or result of
adrenal insufficiency. Our objective was to clarify the relationship between serum MIF and adrenal
function in the HPA axis of sepsis patients using the adrenocorticotropic hormone (ACTH)
stimulation test.
Methods: An observational study was performed in a university intensive care unit over a two-
year period. Of 64 consecutive sepsis patients, 41 were enrolled. The enrolled patients underwent
an ACTH stimulation test within 24 h of the diagnosis of severe sepsis or septic shock. Clinical and
laboratory parameters, including serum MIF and cortisol, were measured.
Results: Based on their responses to the ACTH stimulation test, the patients were divided into a
normal adrenal response (NAR) group (n = 22) and an adrenal insufficiency (AI) group (n = 19).
The AI group had significantly more septic shock patients and higher prothrombin time ratios,
serum MIF, and baseline cortisol than did the NAR group (P < 0.05). Serum MIF correlated
significantly with the SOFA (Sequential Organ Failure Assessment) score, prothrombin time ratio,
and delta max cortisol, which is maximum increment of serum cortisol concentration after ACTH
stimulation test (rs = 0.414, 0.355, and -0.49, respectively, P < 0.05). Serum MIF also correlated
significantly with the delta max cortisol/albumin ratio (rs = -0.501, P = 0.001). Receiver operating
characteristic curve analysis identified the threshold serum MIF concentration (19.5 ng/mL, P =
0.01) that segregated patients into the NAR and AI groups.
Conclusions: The inverse correlation between serum MIF and delta max cortisol or the delta max
cortisol/albumin ratio suggests that high serum MIF reflects an insufficient adrenal response in the
HPA axis. Serum MIF could be a valuable clinical marker of adrenal insufficiency in sepsis patients.
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Background
Sepsis remains one of the main causes of death in inten-
sive care units, despite enormous clinical efforts to coun-
ter it. Although several new interventions for severe sepsis
and septic shock have been introduced, few trials have led
to a dramatic improvement in mortality [1-7].
It has recently been suggested that decreased adrenal ster-
oid levels during stress (adrenal insufficiency) or tissue
resistance to glucocorticoid (GC) are aggravating factors
in critically ill patients [8,9]. Adrenal insufficiency, which
is commonly diagnosed with the adrenocorticotropic hor-
mone (ACTH) stimulation test, affects the efficacy of GC
in the treatment of sepsis and other inflammatory diseases
[8,9]. This observation suggests that GC remains an
encouraging therapeutic agent for sepsis. Several reports
have suggested that GC has beneficial effects [10,11],
whereas other studies have indicated that it is not only
ineffective, but also harmful [12,13]. To render GC ther-
apy successful in the treatment of sepsis, it is necessary to
modulate the inflammatory balance involving GC.
In the present study, we focused on macrophage migra-
tion inhibitory factor (MIF) as an indicator of adrenal
insufficiency. MIF was first discovered in 1966 as a T-cell
cytokine released in the delayed-type hypersensitivity
reaction [14]. It has been studied as an immunoneuroen-
docrine mediator released by various cells, including pitu-
itary cells, macrophages, monocytes, and vascular
endothelial cells, in critically ill patients [15,16]. Interest-
ingly, the unique characteristics of MIF specifically coun-
teract GC-induced anti-inflammatory activity, and low
concentrations of GC induce MIF production by macro-
phages [17,18]. These facts suggest that MIF and GC are
reciprocally involved in regulating the inflammatory and
anti-inflammatory balance [18]. Therefore, serum MIF
and GC might be indicators of the inflammatory/anti-
inflammatory balance in sepsis patients.
We hypothesized that serum concentrations of MIF are
associated with the changes in serum 4 cortisol that occur
after ACTH stimulation in sepsis patients.
Methods
Patients
This study was approved by our Institutional Review
Board in Yamaguchi University Hospital. We obtained the
informed consent of the patients' families or next of kin at
the time of enrolment. Patients admitted between May
2006 and May 2008, and who met the criteria for severe
sepsis or septic shock, were prospectively assessed [19].
Figure 1 shows the selection of the patients. Sixty-four
patients were assessed for eligibility for this study, and 23
patients were excluded. The ACTH stimulation test was
performed in the 41 enrolled patients, of whom 26 had
severe sepsis and 15 had septic shock. The sites of infec-
tion are listed in Table 1, as determined based on clinical
manifestations, positive culture samples, X-ray films, or
computed tomographic imaging.
ACTH stimulation test and patient classification
The ACTH stimulation test was performed in all enrolled
patients within 24 h of the diagnosis of severe sepsis or
septic shock. Synthetic ACTH (tetracosactide acetate, 0.25
mg) was administered intravenously, and serum cortisol
concentrations were measured before (baseline) and 30
and 60 min after ACTH administration. The maximum
increment in the serum cortisol concentration is desig-
nated the "delta max cortisol." To estimate the level of free
cortisol, a normalized value for serum albumin (cortisol/
albumin ratio) was used as an index of free cortisol.
Patients were divided into two groups: the normal adrenal
response group (NAR group; delta max cortisol ≥ 9 μg/dL
and random baseline ≥ 10 μg/dL) and the adrenal insuffi-
ciency cortisol group (AI group; delta max cortisol < 9 μg/
dL or random baseline cortisol < 10 μg/dL), based on pre-
vious reports (Figure 1) [8,9,20-22]. None of the patients
presented a random baseline cortisol concentration below
10 μg/dL.
Blood sampling, measurement of serum MIF and cortisol, 
and other laboratory data
Arterial blood samples were centrifuged at 3,000 × g or 10
min after incubation for at least 30 min at 4°C. The super-
natant (serum) was stored in sterile tubes and frozen at -
80°C. Serum MIF concentrations were measured using an
enzyme-linked immunosorbent assays (ELISA) (human
MIF ELISA kit, Sapporo I.D.L., Japan). The serum sample
and an enzyme-labelled antibody were injected onto a
solid phase (ELISA plate) that contained a mouse mono-
clonal antibody, so that the serum MIF was sandwiched
between the mouse monoclonal antibody and the
enzyme-labelled antibody. The plate was cleaned with
washing solution to remove any unbound antibody. The
bound enzyme-labelled antibody was subjected to a
colorimetric reaction and the colour intensity was meas-
ured at 450 nm.
The serum cortisol concentrations were measured with an
enzyme immunoassay (ST AIA-PACK CORT, TOSOH-
AIA, Japan). The cortisol in the test sample competed with
the enzyme-labelled cortisol for a limited number of
binding sites on a cortisol-specific antibody, which was
immobilized on magnetic beads. The beads were washed
to remove the unbound enzyme-labelled cortisol and
then incubated with the fluorogenic substrate 4-methyl-
umbelliferyl phosphate. The amount of enzyme-labelled
cortisol that bound to the beads was inversely propor-
tional to the cortisol concentration in the test sample. ABMC Infectious Diseases 2009, 9:209 http://www.biomedcentral.com/1471-2334/9/209
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standard curve, based on a range of known concentra-
tions, was constructed and the unknown cortisol concen-
trations were calculated using this curve. The measured
cortisol value is a total one.
Statistical analysis
The data are presented as medians and interquartile
ranges. Comparisons between the NAR 6 group and the AI
group were made using the Mann-Whitney U test and the
χ2 test. The correlations between the serum MIF concen-
trations and the other clinical and laboratory parameters
were analyzed with Spearman's correlation coefficient
(rs). Receiver operating characteristic (ROC) curve analy-
sis was used to determine the threshold of MIF that
allowed the segregation of the patients into different
groups. All analyses were performed with the SPSS soft-
ware, version 11.01 (SPSS, Chicago, IL, USA). Two-sided
P values of < 0.05 were considered significant.
Results
Comparison of the NAR and AI groups
The enrolled patients were divided into two groups: the
NAR group (n = 22) and the AI group (n = 19), based on
the results of the ACTH stimulation test (Table 1). The
number of septic shock patients was significantly greater
in the AI group than in the NAR group. Mortality was not
significantly different between the two groups. None of
the clinical and laboratory data, with the exception of the
prothrombin time ratio, were significantly different
between the two groups. There was also no difference
between the two groups regarding the site of infection.
Study flow diagram Figure 1
Study flow diagram. Sixty-four septic patients were assessed for their eligibility for this study. Of these, 23 were excluded 
and 41 were enrolled. All the enrolled patients underwent an ACTH stimulation test and were divided into two groups: the 
normal adrenal response group (NAR group) and the adrenal insufficiency group (AI group).BMC Infectious Diseases 2009, 9:209 http://www.biomedcentral.com/1471-2334/9/209
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Table 1 presents a comparison of serum MIF, baseline cor-
tisol, and the results of the ACTH stimulation test between
the two groups. Serum MIF was significantly higher in the
AI group than in the NAR group. Baseline cortisol was sig-
nificantly higher in the AI group than in the NAR group,
and the baseline cortisol/albumin ratio, which was used
as an index of baseline free cortisol, was relatively but not
significantly higher in the AI group. Delta max cortisol
was significantly lower in the AI group, and the delta max
cortisol/albumin ratio was significantly lower in the AI
group than in the NAR group.
Correlations between serum MIF and clinical and 
laboratory parameters
Table 2 lists the correlations between the serum MIF con-
centrations and the clinical and laboratory parameters.
Serum MIF correlated inversely with delta max cortisol
and the delta max cortisol/albumin ratio. The Sequential
Organ Failure Assessment (SOFA) score and prothrombin
time ratio also correlated significantly with the serum MIF
concentration. Serum MIF showed no correlation with
baseline cortisol or the baseline free cortisol index.
Table 1: Comparison of the clinical and laboratory characteristics of the normal adrenal response group and the adrenal insufficiency 
group of patients
NAR group (n = 22) AI group (n = 19) P value
Age (yrs) 67 (50-71) 68 (55-74) 0.574
Male (n) 14 16 0.233
APACHE II 27 (21-29) 27 (19-32) 0.582
SOFA score 9 (5-11) 8 (6-11) 0.793
JAAM DIC score 3.0 (1.75-5.0) 3.0 (2.0-5.0) 0.433
Severe sepsis/septic shock (n) 19/3 7/12 0.001
Survivors/non-survivors (n) 16/6 13/6 0.763
Albumin (g/dL) 2.1 (1.7-2.5) 2.0 (1.6-2.2) 0.636
Prothrombin time ratio 1.2 (1.1-1.3) 1.3 (1.2-1.5) 0.025
MIF (ng/mL) 16.6 (14.5-20.1) 23.8 (17.6-44.5) 0.010
Baseline cortisol (μg/dL) 18.9 (14.3-25.3) 27.6 (17.6-46.8) 0.028
Baseline cortisol/albumin ratio 10.3 (8.6-13.0) 15.1 (9.4-20.0) 0.053
Delta max cortisol (μg/dL) 15.5 (9.9-19.6) 4.6 (1.4-7.3) < 0.001
Delta max cortisol/albumin ratio 7.5 (6.0-8.5) 2.3 (0.8-3.3) < 0.001
Site of infection (n)
Respiratory tract 11 7
Skin and soft tissue 3 5
Gastrointestinal tract 2 3
Urinary tract 1 2
Peritonitis 2 1
Meningitis 1 0
Infectious endocarditis 1 0
Unknown 0 1
All values are presented as medians (interquartile ranges).
NAR: normal adrenal response; AI: adrenal insufficiency; APACHE II: Acute Physiology and Chronic Health Evaluation II; SOFA score: Sequential 
Organ Failure Assessment score; JAAM DIC score: Disseminated Intravascular Coagulation score established by the Japanese Association for Acute 
Medicine; Prothrombin time ratio: the ratio of the actual prothrombin time vs the normal control prothrombin time; MIF: macrophage migration 
inhibitory factor; Delta max cortisol: maximum increment in the cortisol concentration caused by the adrenocorticotropic hormone stimulation 
test.
Table 2: Correlations between serum macrophage migration 
inhibitory factor and other clinical and laboratory parameters
rs P value
APACHE II 0.144 0.371
SOFA score 0.414 0.007
JAAM DIC score 0.267 0.092
Albumin -0.290 0.860
Prothrombin time ratio 0.355 0.024
Baseline cortisol 0.212 0.182
Baseline cortisol/albumin ratio 0.237 0.135
Delta max cortisol -0.490 0.001
Delta max cortisol/albumin ratio -0.501 0.001
rs: Spearman's correlation coefficient; APACHE II: Acute Physiology 
and Chronic Health Evaluation II; SOFA score: Sequential Organ 
Failure Assessment score; JAAM DIC score: Disseminated 
Intravascular Coagulation score established by the Japanese 
Association for Acute Medicine; Prothrombin time ratio: the ratio of 
the actual prothrombin time vs the normal control prothrombin time; 
Delta max cortisol: maximum increment in the cortisol concentration 
caused by the adrenocorticotropic hormone stimulation test.BMC Infectious Diseases 2009, 9:209 http://www.biomedcentral.com/1471-2334/9/209
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ROC curve analysis
An ROC curve analysis was conducted to determine the
threshold serum MIF concentration that segregated the
patients into the NAR and AI groups (Figure 2). The area
under the ROC curve was 0.734 and the MIF concentra-
tion value with the highest sensitivity and specificity was
the reference value of 19.5 ng/mL, with a sensitivity of
0.737 and specificity of 0.773 (P = 0.01).
Discussion
MIF is secreted by monocytes/macrophages after infec-
tious stimulation and acts as a pro-inflammatory
cytokine. An increase in MIF in critically ill patients and a
correlation between serum MIF and early death in patients
with severe sepsis have previously been reported [23-26].
It is noteworthy that MIF counteracts GC-induced anti-
inflammatory activity and that low concentrations of GC
induce MIF production by macrophages [17,18]. We spec-
ulated that the serum MIF concentration might reflect
adrenal function in the hypothalamo-pituitary-adrenal
(HPA) axis in patients with sepsis.
The main and novel result of this study is the inverse cor-
relation between the serum MIF concentration and delta
max cortisol (Table 2). A correlation between serum MIF
and total baseline cortisol was reported previously
[26,27]. However, this is the first report to suggest an asso-
ciation between MIF and the adrenal response. In general,
free cortisol is preferable to total cortisol in evaluating the
adrenal function of the HPA axis, especially during exces-
sive inflammation [28]. Free cortisol has physiological
effects, but the direct measurement of free cortisol is com-
plicated. Therefore, the ratio of total cortisol/albumin has
been used as an index of free cortisol when evaluating
HPA axis function [29,30]. Changes in the free cortisol
index reflect the status of the inflammatory balance regu-
lated by the HPA axis. In this study, a significant inverse
correlation between serum MIF and the delta max corti-
sol/albumin ratio was observed (Table 2). Consequently,
high serum MIF is considered to be associated with insuf-
ficient activation of the HPA axis in patients with severe
sepsis or septic shock.
The dose of synthetic ACTH (0.25 mg) used in the present
study was about 100-fold higher than the ACTH levels
observed under physiological stress. Therefore, the serum
cortisol concentration might reach its maximum level
after the ACTH stimulation test. This means that the delta
max cortisol value reflects the reserve capacity of the adre-
nal gland. A low delta max cortisol suggests that the
patient's adrenal glands are already highly activated and
that his/her cortisol production isare insufficient to cope
with the added stress. Therefore, the baseline cortisol
observed in the AI group could be insufficient to accom-
modate serious stress, even though it was significantly
higher than that in the NAR group (Table 1). Therefore,
the inverse correlation between serum MIF and delta max
cortisol indicates that a high concentration of serum MIF
might be associated with a relative insufficiency of innate
cortisol activity or HPA axis dysfunction (Table 2).
The secretion of cortisol and the translocation of the GC
receptor complex into the nucleus are impaired in criti-
cally ill patients [31]. The pathophysiological condition of
reduced steroid production (adrenal insufficiency) or tis-
sue resistance to GC activity during critical illness is called
"critical -illness-related corticosteroid insufficiency"
(CIRCI) [22]. CIRCI is defined as inadequate cellular cor-
ticosteroid activity for the additional stress experienced by
the patient. Although the baseline cortisol concentration
and baseline cortisol/albumin ratio in the AI group were
higher than those in the NAR group (Table 1), they were
not high enough to suppress the inflammatory response
in the AI group patients. As a result, we could determine
the threshold serum MIF level that defines adrenal insuf-
ficiency. Using ROC curve analysis, we demonstrated that
the threshold serum MIF level that segregated patients
into the NAR group and AI group was 19.5 ng/mL and
that the maximum sensitivity and specificity of this meas-
ROC curve of serum MIF concentration used to segregate  patients into the NAR and AI group Figure 2
ROC curve of serum MIF concentration used to seg-
regate patients into the NAR and AI group. The area 
under the curve was 0.734, and the maximum sensitivity and 
specificity were 0.737 and 0.773, respectively. The reference 
value for the segregation of patients into the two groups was 
19.5 ng/mL (P = 0.01).BMC Infectious Diseases 2009, 9:209 http://www.biomedcentral.com/1471-2334/9/209
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ure were 0.737 and 0.773, respectively (Figure 2). These
results suggest that serum MIF is a good clinical marker of
adrenal insufficiency.
In the present study, the SOFA score correlated signifi-
cantly with serum MIF (Table 2). This result is consistent
with previous reports that serum MIF is related to the
severity of sepsis and mortality [23-26]. Macrophages con-
tain a certain amount of pre-formed MIF, which is rapidly
released with infectious stimulation [15]. MIF secretion
from macrophages also occurred under challenge with
low concentrations of lipopolysaccharide, which were 10-
to 100-fold lower than the concentration necessary to
induce tumor necrosis factor α. MIF induced cytokine
release, neutrophil accumulation, and persistent inflam-
mation [15,32]. It has also been reported that the admin-
istration of recombinant MIF increased the systemic
toxicity of endotoxin, whereas anti-MIF antibody fully
protected mice from endotoxic shock and death [17].
Consequently, we consider that the measurement of the
serum MIF concentration in the early phase of sepsis is
useful in detecting and even treating inflammatory imbal-
ance and organ failure.
The correlation between serum MIF and the prothrombin
time ratio indicates that an increase in the prothrombin
time ratio predicts sequential organ failure. Moreover, the
increase in serum MIF may indicate coagulopathic dys-
function. MIF has recently become both an attractive
marker for prognostic prediction and a therapeutic target,
because levels of MIF are associated with the mechanisms
of both inflammation and coagulation in sepsis [33]. The
main target of sepsis treatment is inflammatory modula-
tion, in which the activation of the HPA axis is involved.
The relationship between MIF and delta max cortisol in
the HPA axis network has been demonstrated in 10 the
present study.
Because the measurement of serum MIF concentrations is
not complicated, it is feasible during routine laboratory
practice. Unlike the ACTH stimulation test, we can repeat-
edly measure the MIF concentration within a short time
period. Daily monitoring might be useful in evaluating
the inflammation status and adrenal responses of criti-
cally ill patients.
There are several limitations to this study. First, additional
information is required to clarify the detailed mechanism
involving adrenal function, the HPA axis, and MIF in crit-
ically ill patients. Second, we used the cortisol/albumin
ratio as the index of free cortisol to evaluate the adrenal
function in the HPA axis. Although measurement of the
free cortisol value is preferable, this procedure is not cur-
rently widely available. However, it is probable that with
improvements in laboratory techniques and increased
clinical demand, the method will become commercially
available [34]. Third, the number of patients enrolled in
this study was relatively small. We intend to continue this
study of the relationship between MIF and the HPA axis.
Conclusions
An inverse correlation was demonstrated between MIF
and delta max cortisol or the delta max cortisol/albumin
ratio in patients with severe sepsis or septic shock. MIF
may play an important role in sepsis as a pro-inflamma-
tory cytokine and an inflammatory modulator, and may
be a marker of the severity of the associated adrenal insuf-
ficiency.
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